Filing Flows › ImmunityBio (IBRX) › Product revenue, net revenue
ImmunityBio (IBRX) Product revenue, net revenue by quarter
ImmunityBio's Product revenue, net revenue was $50.7M in Q2 2026 (second quarter 2026), +15% from Q1 2026. Over the last 7 quarters it ranged from $7.2M (Q4 2024) to $50.7M (Q2 2026).
| Quarter | Product revenue, net revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $50.7M | +15% | +92% |
| Q1 2026 | $44.2M | +15% | +168% |
| Q4 2025 | $38.3M | +20% | +431% |
| Q3 2025 | $31.8M | +20% | — |
| Q2 2025 | $26.4M | +60% | — |
| Q1 2025 | $16.5M | +129% | — |
| Q4 2024 | $7.2M | — | — |
Q2 2026 at a glance
ImmunityBio, Q2 2026: revenue $51.2M (+94% year over year), operating margin -120.4%, net loss $230M, operating cash flow −$66.5M. The chart follows the revenue to costs, profit and cash.
Questions
What is ImmunityBio's Product revenue, net revenue?
ImmunityBio's Product revenue, net revenue was $50.7M in Q2 2026 (second quarter 2026), +15% from Q1 2026.
How has ImmunityBio's Product revenue, net revenue changed?
Over the last 7 quarters it ranged from $7.2M (Q4 2024) to $50.7M (Q2 2026).